The biopharma industry faces a relentless demand for evidence of real-world effectiveness (RWE), safety, and value throughout the product lifecycle to complement the clinical trial-based be
Although it might seem like AI is the newest and hottest innovation in the industry, medical affairs professionals have been using some form of it for decades
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh